Pharming Group (NASDAQ:PHAR) Earns Buy Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Pharming Group (NASDAQ:PHAR) in a research note released on Thursday morning,Benzinga reports. They currently have a $37.00 target price on the stock.

A number of other research analysts have also recently commented on PHAR. Jefferies Financial Group began coverage on shares of Pharming Group in a research report on Monday, December 9th. They issued a “buy” rating and a $14.00 target price on the stock. Oppenheimer upped their target price on shares of Pharming Group from $30.00 to $39.00 and gave the company an “outperform” rating in a research report on Friday, March 14th.

Pharming Group Trading Down 0.3 %

Shares of PHAR stock opened at $8.90 on Thursday. The company’s 50-day moving average price is $8.90 and its 200-day moving average price is $8.62. The company has a current ratio of 3.53, a quick ratio of 2.76 and a debt-to-equity ratio of 0.41. The stock has a market cap of $605.75 million, a price-to-earnings ratio of -34.25 and a beta of -0.10. Pharming Group has a twelve month low of $6.65 and a twelve month high of $11.30.

Pharming Group (NASDAQ:PHAR) last posted its earnings results on Thursday, March 13th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.02). Pharming Group had a negative net margin of 6.09% and a negative return on equity of 7.65%. The company had revenue of $92.70 million during the quarter, compared to analyst estimates of $76.67 million. As a group, equities analysts predict that Pharming Group will post -0.2 earnings per share for the current year.

Institutional Trading of Pharming Group

A hedge fund recently raised its stake in Pharming Group stock. Silverberg Bernstein Capital Management LLC grew its holdings in shares of Pharming Group (NASDAQ:PHAR) by 16.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 47,997 shares of the company’s stock after purchasing an additional 6,887 shares during the period. Silverberg Bernstein Capital Management LLC owned about 0.07% of Pharming Group worth $483,000 as of its most recent SEC filing. 0.03% of the stock is owned by institutional investors.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.